Biomedtracker’s Best Of J.P. Morgan: 15 Companies To Watch
Highlights from Biomedtracker’s daily reports from the J.P. Morgan Healthcare Conference include products advancing in NASH, competition in CAR-T and more.
You may also be interested in...
The Phase III study for brexanolone in super-refractory status epilepticus did not meet its primary endpoint, but Sage is optimistic about the drug's prospects in postpartum depression and its earlier-stage SAGE-217.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.